AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein phosphatase methylesterase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y570

UPID:

PPME1_HUMAN

Alternative names:

-

Alternative UPACC:

Q9Y570; B3KMU6; B5MEE7; J3QT22; Q8WYG8; Q9NVT5; Q9UI18

Background:

Protein phosphatase methylesterase 1 (PPME1) plays a crucial role in cellular processes by demethylating proteins that have undergone reversible carboxymethylation. It specifically targets and demethylates PPP2CB and PPP2CA, key components in the protein phosphatase 2 (PP2A) complex, which is essential for cell cycle regulation, signal transduction, and other critical cellular activities. By binding to PPP2CA, PPME1 displaces the manganese ion, rendering the enzyme inactive.

Therapeutic significance:

Understanding the role of Protein phosphatase methylesterase 1 could open doors to potential therapeutic strategies. Its involvement in the regulation of PP2A, a complex pivotal to numerous cellular functions, highlights its potential as a target in diseases where PP2A activity is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.